An interventional study of Cerebral autoregulation monitoring in Cardiac Disease, sponsored by IRCCS Policlinico S. Donato. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by IRCCS Policlinico S. Donato · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Heart Diseases with a site in Italy — 31 open to participants now, 40 under way, 4 of them phase 3. Heart Diseases · Italy.
Among the 102 studies in Heart Diseases with a site in Italy, this one is the 51st largest by planned enrollment of the 66 interventional ones that give a count, is one of 10 that started in 2023, is one of 31 with no phase, reaches primary completion later than 14 of the 39 other live ones, and was the 71st registered.
2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.
Browse Heart Diseases studies →31 of the 102 studies in Heart Diseases with a site in Italy are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in Italy, United States, Brazil and 6 more countries
Ages 6+
Fondazione Don Carlo Gnocchi ETS · Sites in Italy
Ages 30–75
Kiniksa Pharmaceuticals International, plc · Sites in Italy, United States, Canada and 7 more countries
Ages 18–80
Fondazione Ricerca e Innovazione Cardiovascolare ETS · Sites in Italy
Eli Lilly and Company · Sites in Italy, Argentina, Australia and 35 more countries
Ages 50+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 11 · Phase 3 21 · Phase 4 4
First in 2002; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 104 is below the median of 129 across 931 interventional studies indexed under Heart Diseases.
Median enrollment 444 across the 66 interventional studies, 300 across the 35 observational. Of the 54 that completed or were terminated, 19 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
54 of 102 have an industry lead sponsor. The 10 most frequent:
IRCCS Policlinico S. Donato is the lead sponsor of 105 studies on the registry; 53 are open to participants now.
IRCCS Policlinico S. Donato has 8 studies filed under Heart Diseases — fewer than ten, so there is no comparison to draw.
11 of the studies in Heart Diseases with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07119424Chiara LanzaniMultidisciplinary Dissection of Renal and Metabolic Effects of Glyfozines on Elderly Patients: From Molecular Aspects to Clinical Indications | 2026-11 |
| NCT06799780IRCCS Azienda Ospedaliero-Universitaria di BolognaStudy on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing | 2026-11-30 |
| NCT03339115Cardiovalve Ltd.AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System | 2026-12-31 |
| NCT07157696Università degli Studi di FerraraAdvanced Respiratory Monitoring and Oxygen Therapy in Chronically Ill Patients With Acute Respiratory Failure | 2026-12-31 |
| NCT05786274IRCCS Policlinico S. DonatoPredicting Cerebrovascular Adverse Events Post Cardiac Surgery | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 102 studies in Heart Diseases with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aims of this study are: i) to assess cerebral autoregulation and autonomic control within the different phases of cardiac surgery with cardiopulmonary bypass; ii) to compare cerebral autoregulation measures derived via cerebral blood flow velocity estimated by transcranial Doppler device with simpler measurements derived from near infrared spectroscopy; iii) to develop a predictive model of postoperative cerebrovascular outcome (overt or silent stroke) based on the extracted indices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be enrolled before cardiac surgery with cardiopulmonary bypass (CPB) and monitored until after the surgery. Patients enrolled will undergo diffusion weighted magnetic resonance imaging and will be administered with cognitive tests one day before surgery and within one week after surgery. Cerebral blood flow velocity as derived from transcranial Doppler recordings will be acquired from the middle cerebral artery synchronously with arterial pressure, invasively derived from the radial artery, and with the electrocardiogram as derived from patient's monitor. Signals will be acquired before anesthesia induction (BASAL), after anesthesia induction and intubation of the chest (ANESTH) and during CPB (CPB). Each acquisition will last at least 5 minutes and will be prolonged to the maximum possible length in keeping with clinical scheduling. Partial pressure of carbon dioxide and other clinical parameters will be acquired too during the intervention.
Diagnostic Test: Cerebral autoregulation monitoring
Perioperative characterization of cerebral autoregulation and autonomic function; characterization of adverse events after surgery
Autoregulation index (ARI)
ARI is an index describing the state of cerebral autoregulation from mean cerebral blood velocity and mean arterial pressure. It ranges between 1 and 9. ARI\>4 means working autoregulation. ARI\<4 means impaired autoregulation. It will be computed for all participants in BASAL, ANESTH, CPB.
Time frame: 36 months
Cerebral Oxymetry index (CoX)
CoX is an index describing the state of cerebral autoregulation derived from NIRS and mean arterial pressure. It ranges between 0 and 1. CoX = 1 means perfect coupling. Cox=0 means uncoupling. It will be computed for all participants in BASAL, ANESTH, CPBasurements derived from near infrared spectroscopy
Time frame: 36 months
number of patients developing cerebrovascular adverse events
The number of patients developing cerebrovascular adverse events will be assessed by the presence of positive lesions as detected by DW-MRI.
Time frame: 36 months
Baroreflex sensitivity
Baroreflex sensitivity will be measured in ms/mmHg. A higher value means a better baroreflex regulation. It will be computed in all participants during BASAL, ANESTH, CPB.
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.
Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 44 months is above that.
Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.